According to newspaper reports Lupin Ltd., the Indian generic-drug maker, is looking for acquisitions in Brazil and Mexico to expand its revenue from the Latin American region.
The company plans to spend $50 million to $75 million on each purchase, according to S. Ramesh, president of finance and planning. Lupin is looking for companies that have a strong marketing relationship with physicians and will make the acquisitions soon, he said, without providing a more specific timeframe.
Lupin generates 10 percent of revenue from a sales region that includes Latin America and Europe. Ramesh was quoted as saying “Latin America is the next stop for us, in so far as of acquisitions...Recognition with the doctor is the most important consideration for the purchases¨.